Standard Life (LSE:SDLF) offers one of the higher yields among London's largest companies, but the shares have recently had to absorb a large sale by a long-standing investor. With a major Acquisition also approaching completion, the focus is on whether cash generation can continue to support the payout. The answer, in short, depends less on reported profit than on how a retirement and savings group measures its own strength.

A high Yield with a steady record

As of 7 October 2026, the retirement specialist, which changed its name from Phoenix Group Holdings in March, has an annual Dividend of 55.4p per share. Its latest declared payment was the 28.05p interim. The trailing 12-month yield is 6.5% and the indicated yield 6.4%, levels that place it firmly among income-focused holdings.

The group has paid dividends for 17 consecutive years and has raised them for 11 years in a row. Annual growth of 2.6% is deliberately measured, and it matches the 2.6% rise in the Interim Dividend announced with half-year results in September, from 27.35p to 28.05p.

A yield of this level is one of the highest in the index, and a high yield always deserves a closer look, because it can signal either generous distributions or doubts about their durability. In this case the steady, low single-digit increases point to a board that prefers a predictable path over a large payout that might later need to be trimmed.

Why the Payout Ratio is negative

The payout ratio recorded is minus 114.1%, a figure that looks alarming at first glance. A negative ratio arises when a company pays a dividend while reporting a loss on a per-share basis, so it does not provide a meaningful measure of Earnings cover here. Standard Life reported an IFRS loss after tax of £179m in the first half, compared with a £156m loss a year earlier.

For life insurers and long-term savings businesses, statutory profit can be heavily affected by hedging and accounting treatment, which is why management directs investors to cash measures instead. Those measures are the ones that actually fund the dividend, because cash is what ultimately reaches shareholders. Operating cash generation in particular shows how much cash the existing book of Business releases after meeting its obligations. Operating cash generation rose 6% to £745m in the first half and total cash generation increased 15% to £900m. The company also reported IFRS adjusted operating profit up 25% to £563m and said it expects its IFRS net asset position to turn positive in 2027.

A negative ratio should not be dismissed entirely, however. It is a reminder that the dividend rests on the continued flow of cash from the back book of existing policies and on the health of the Solvency position rather than on reported profits.

Capital and the Aegon deal

The backing for the dividend comes from the Balance Sheet as much as from the income statement. The Shareholder Capital coverage ratio was 169% at the half-year stage, down from 176% at the end of 2025 but in the upper half of the company's 140% to 180% target range. The Solvency II Leverage Ratio fell to 29%, reaching its target of about 30% ahead of schedule. Solvency measures of this kind show how much capital an insurer holds against the risks on its balance sheet, and regulators and boards both watch them closely before approving distributions.

The £2bn purchase of Aegon UK, announced in April, is expected to complete around the end of 2026, subject to regulatory approval. The consideration includes 181m new Standard Life shares, which will increase the number of shares receiving a dividend. The acquisition therefore needs to add enough cash to pay for that larger dividend bill while preserving the group's progressive approach.

This is the central test for Standard Life (LSE:SDLF). If the acquired business contributes cash generation in proportion to the shares issued, the per-share dividend can continue to rise. If integration takes longer or costs more than planned, the larger share count would put the same cash pool under greater pressure.

Aberdeen steps back

In October, Aberdeen Group (LSE:ABDN) sold 52m Standard Life shares, reducing its holding to 5.3%, which took it below the level needed to nominate a director. Its board nominee, Siobhan Boylan, stepped down on 12 October. A sale of that size can create short-term pressure on a share price, although it does not by itself change the fundamentals of the business. Share prices often recover once the extra Supply has been absorbed, but that outcome cannot be assumed.

For dividend purposes, the relevance is indirect. A holder selling shares does not alter the cash generated by the business or the amount the board intends to pay. The matter is mainly one of market supply: shares that were held by a single large investor are being spread across a wider base of owners, and further sales could continue to attract attention until the position is fully resolved.

What to watch

The main milestone is completion of the Aegon UK transaction, followed by the full-year results, when the company will update on its £5.1bn three-year cash target, of which £4.4bn had been achieved by the half-year stage. Investors should also monitor the capital coverage ratio after the deal, which will show how much capital the larger group holds, and whether the remaining Aberdeen stake is sold down further.

The 12th consecutive annual increase will depend on the cash numbers remaining on track. For anyone assessing LSE:SDLF as an income holding, the cash generation figures, the capital coverage ratio and the way the enlarged share count is absorbed will be more informative than the statutory loss, which is distorted by market movements and accounting treatment, and they are likely to shape the outlook for the payout over the next few years, including whether the 12th annual increase arrives on schedule.